Should We Start Thinking Again About Bioresorbable Stents?

Coronary revascularization with drug-eluting stents (DES) is very frequent, especially in acute coronary syndromes, but these metallic stents are permanent foreign bodies that activate the entire inflammatory system.

¿Deberíamos comenzar a pensar nuevamente en los stents bioabsorbibles?

Using bioresorbable stents (BRS) emerged as an alternative to this challenge. Although the initial results of the ABSORB study were not as expected (probably due to a lack of technological development), a new stage in the development of these devices could begin with the new second-generation MAGMARIS stent.

Researchers conducted a single-center analysis of bioresorbable stents implanted from 2012 to 2020 in patients with acute coronary syndromes, following the evolution of the MAGMARIS (MAG) stent in 193 patients and the ABSORB (ABS) stent in 160 patients.

The primary endpoint (PEP) was a safety composite that included all-cause mortality, infarction, and definite or probable thrombosis at 30 days and 1 year. 

The mean age was 65 years, 37% of patients had diabetes, 85% experienced hypertension, 4% suffered from atrial fibrillation, and 38% had a prior angioplasty. Patients who received MAG had higher rates of unstable angina and non-ST-segment-elevation acute myocardial infarction. Similarly, they presented a higher ejection fraction (60% vs. 55%; p < 0.001).

Read also: A Nod to Catheter-Guided Thrombolysis in Pulmonary Thromboembolism.

In all cases, correct pre-dilatation and preparation of the lesion for stent implantation was performed. The most frequently treated artery was the anterior descending (AD): it received 1.2 stents/patient and double antiplatelet therapy.

At 30 days and at 1 year, the PEP was in favor of MAG (0% vs. 3.1%; p = 0.018, and 1.5% vs. 8.1%; p = 0.003), led by the presence of infarction and stent-thrombosis at 30 days in patients who received ABS. 

At 30 days, target-lesion failure was also lower in MAG. At 12 months MAGMARIS presented lower target-lesion failure, led by lower presence of stent-thrombosis and infarction.

Conclusion

Data from the present study show greater safety and a more favorable clinical evolution of the MAGMARIS Magnesium bioresorbable stent compared with the Absorb polymer stent.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Outcomes of the two generations of bioresorbable scaffolds (Magmaris vs. Absorb) in acute coronary syndrome in routine clinical practice.

Reference: Piotr Rola, et al. Cardiology Journal, ON LINE FIRST DOI: 10.5603/CJ.a2022.0047. 


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

QFR vs. FFR: Is Coronary Revascularization Deferral Safe? Results from a FAVOR III Sub-Analysis

In cases of intermediate coronary lesions, functional assessment is recommended to aid the decision-making process regarding revascularization. There are several tools currently used to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...